





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

A61K 38/18, 31/7088, A61P 25/32, 25/28

(11) International Publication Number:

WO 00/53217

(43) International Publication Date:

14 September 2000 (14.09.00)

(21) International Application Number:

PCT/US00/06364

A2

(22) International Filing Date:

10 March 2000 (10.03.00)

(30) Priority Data:

09/267,511

12 March 1999 (12.03.99)

US

(71) Applicants (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Bethesda, MD 20852 (US). RAMOT OF TEL AVIV UNIVERSITY [IL/IL]; Tel Aviv University, 69978 Tel Aviv (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRENNEMAN, Douglas, E. [US/US]; 10601 Santa Anita Terrace, Damascus, MD 20872 (US). SPONG, Catherine, Y. [US/US]; 3730 North 25th Street, Arlington, VA 22207 (US). GOZES, Illana [IL/IL]; Hamal Street 14, Ramat Hasharon (IL). BASSAN, Merav [IL/IL]; Ziporen Street 15A, Givat Poleg, Natania, Hod Hasharon (IL). ZAMOSTIANO, Rachel [IL/IL]; Yeshuron Street 17, Hod Hasharon (IL).

(74) Agents: CHOI, Kathleen et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: PREVENTION OF FETAL ALCOHOL SYNDROME AND NEURONAL CELL DEATH WITH ADNF POLYPEPTIDES

(57) Abstract

The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g., ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.